TerrAscend Corp. (TSNDF) Fair Value & Analysis
Healthcare · US · Market cap $234M
TerrAscend Corp.
TSNDF · US
Fair value as of: Aug 13, 2026
From 13 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from $0.9300 to $0.9200 (−1.1%) since Jul 21, 2026. Share price −1.9% over the past month.
Below-average quality, screening 64% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (32/100). That raises the risk this is a value trap rather than a bargain.
- The model range is unusually wide ($0.2300 to $1.71). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.2400 – $11.93 · fair‑value band $0.2300 – $1.71 · the $0.5619 price screens below the $0.9200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
TerrAscend Corp. (TSNDF) currently trades at $0.5619, while our model-based Fair Value estimate is $0.9200, implying the stock looks roughly 63.7% undervalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, TerrAscend Corp. generated revenue of $262M at a net margin of -31.2%. Revenue grew 1.9% year over year. It earns a return on equity of -18.5%. Net debt stands at $189M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.2300 (bear case) to $1.71 (bull case); at $0.5619, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 61% below its 52-week high and 126% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 64%, TSNDF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Multiples ($1.89) versus Asset-Based ($0.2100). Highest evidence: Growth DCF (80).
Notify me when TSNDF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 30 · Market factors (momentum, volatility) 13
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, and Cookies.
Full company description
TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, and Cookies. The company also operates retail dispensaries under the Apothecarium brand name. It serves medical patients and adult-use consumers in North America. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TerrAscend Corp. reported revenue of $261M in FY2025 versus $210M in FY2021, a compound +5.5%/yr. Reported net income was −$86.2M in FY2025.
Watch TSNDF: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 634 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare TerrAscend Corp. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TerrAscend Corp. (TSNDF) overvalued or undervalued?
What is the fair value of TSNDF?
What is the quality score of TSNDF?
What is the revenue of TerrAscend Corp. (TSNDF)?
What is the net profit margin of TSNDF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track TerrAscend Corp. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.